Key result
Proton-pump inhibitor prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding.
Why the study?
How should gastrointestinal bleeding be managed and prevented in patients receiving antiplatelet therapy?
Population
Patients receiving antiplatelet therapy for secondary prevention of acute coronary syndrome and ischemic…
Design
Review
Authors
Loading...
May support immediate antiplatelet resumption after GI hemostasis; leaves open need for randomized confirmation in high-risk patients.
How should gastrointestinal bleeding be managed and prevented in patients receiving antiplatelet therapy?
This review highlights the importance of PPI prophylaxis to prevent GI bleeding and the early resumption of antiplatelet therapy after hemostasis to prevent ischemic events.
Hiroshi Yasuda (2015) conducted a review in Gastrointestinal bleeding in patients receiving antiplatelet therapy. Proton-pump inhibitors (PPIs) was evaluated. Proton-pump inhibitor prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: